MDGL Madrigal Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MDGL

Price (delayed)

$513.02

Market cap

$11.85B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.85

Enterprise value

$11.91B

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 53
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 30

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, ...

Highlights
The revenue has surged by 149% year-on-year and by 13% since the previous quarter
The company's gross profit has surged by 137% YoY and by 11% QoQ
The debt has surged by 181% year-on-year
The company's quick ratio fell by 38% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.madrigalpharma.com

Key stats

What are the main financial stats of MDGL

MDGL stock price

How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
-1.12%
1 week
-3.04%
1 month
-0.72%
1 year
15.72%
YTD
-11.9%
QTD
-4.46%

Financial performance

How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$1.28B
Gross profit
$1.17B
Operating income
-$322.62M
Net income
-$325.1M
Gross margin
91.5%
Net margin
-25.3%
The revenue has surged by 149% year-on-year and by 13% since the previous quarter
The company's gross profit has surged by 137% YoY and by 11% QoQ
Madrigal Pharmaceuticals's operating margin has soared by 58% YoY and by 9% from the previous quarter
The net margin has surged by 54% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does MDGL's price correlate with its fundamentals

Growth

What is Madrigal Pharmaceuticals's growth rate over time

Valuation

What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
22.58
P/S
11.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.27
The EPS has decreased by 11% YoY and by 4% from the previous quarter
The equity is down by 25% year-on-year and by 3.6% since the previous quarter
The stock's price to book (P/B) is 9% less than its 5-year quarterly average of 25.2 but 9% more than its last 4 quarters average of 21.0
The revenue has surged by 149% year-on-year and by 13% since the previous quarter
The P/S is 11% lower than the last 4 quarters average of 13.3

Efficiency

How efficient is Madrigal Pharmaceuticals business performance
The ROS has soared by 56% YoY and by 8% from the previous quarter
The ROE has contracted by 47% YoY and by 13% from the previous quarter
Madrigal Pharmaceuticals's ROIC has increased by 14% YoY
MDGL's return on assets is up by 7% year-on-year

Dividends

What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MDGL.

Financial health

How did Madrigal Pharmaceuticals financials performed over time
Madrigal Pharmaceuticals's total assets is 73% more than its total liabilities
Madrigal Pharmaceuticals's total liabilities has soared by 126% YoY and by 5% from the previous quarter
The company's quick ratio fell by 38% YoY and by 7% QoQ
The debt is 34% smaller than the equity
The debt has surged by 181% year-on-year
The equity is down by 25% year-on-year and by 3.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.